4//SEC Filing
Simonian Nancy A 4
Accession 0000950170-24-120874
CIK 0001556263other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 5:01 PM ET
Size
7.1 KB
Accession
0000950170-24-120874
Insider Transaction Report
Form 4
Simonian Nancy A
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-10-31−40,125→ 0 total→ Common Stock (40,125 underlying) - Exercise/Conversion
Common Stock
2024-10-31+40,125→ 175,783 total
Footnotes (3)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F3]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001359574
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 5:01 PM ET
- Size
- 7.1 KB